Are we closer to personalized therapy in juvenile idiopathic arthritis?

Juvenile idiopathic arthritis (JIA) is the most common rheumatic disorder in children. However, actually this term encompasses a heterogeneous group of disorders. Their classification is based on clinical and laboratory features occurring in the 6 months after the disease onset. Most importantly, different subtypes of JIA can still be associated with permanent disability and significant morbidity.

• Publication year

  2016

• Venue

  Rheumatology

• Publication date

  2016-10-05

• Fields of study

  Medicine

• Identifiers
  DOI 10.5114/reum.2016.62467PMID 27826167PMCID 5090021
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Review of biomarkers in systemic juvenile idiopathic arthritis: helpful tools or just playing tricks?

  2016cited by this paper
• Limits of Peripheral Blood Mononuclear Cells for Gene Expression-Based Biomarkers in Juvenile Idiopathic Arthritis

  2016cited by this paper
• Management of juvenile idiopathic arthritis: hitting the target

  2015cited by this paper
• Advances in biomarkers for paediatric rheumatic diseases

  2015influential reference
• Pharmacogenetics: can genes determine treatment efficacy and safety in JIA?

  2014cited by this paper
• Genome-Wide Data reveals Novel Genes for Methotrexate Response in a Large Cohort of Juvenile Idiopathic Arthritis Cases

  2014cited by this paper
• Update on research and clinical translation on specific clinical areas: From bench to bedside: How insight in immune pathogenesis can lead to precision medicine of severe juvenile idiopathic arthritis.

  2014influential reference
• Personalized therapies in pediatric inflammatory and autoimmune diseases.

  2012cited by this paper
• Biologic predictors of extension of oligoarticular juvenile idiopathic arthritis as determined from synovial fluid cellular composition and gene expression

  2010cited by this paper

• Methotrexate disposition, anti‐folate activity and efficacy in the collagen‐induced arthritis mouse model

  2019cites this paper